根据美国证券交易委员会（SEC）的最新文件披露，生物技术公司伊诺维奥制药已正式暂停并终止了其与投资银行奥本海默公司此前达成的“按市价发行”（ATM）股权发售计划的相关招股说明书。
此项决定意味着，伊诺维奥制药将暂时无法通过该ATM融资机制在公开市场灵活地发售新股以募集资金。ATM发行方式通常允许上市公司在需要时，根据市场情况伺机发行股票，是一种灵活高效的融资工具。此次计划的终止，可能反映出公司当前融资策略的调整，或是基于对市场环境的考量。
市场参与者将密切关注此举对公司未来资金状况及研发管线推进可能产生的影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.